if tirzepatide gets warm Does Make You Cold​? The Do's and Don'ts of

249 13.2.1 MACROECONOMIC OUTLOOK FOR NORTH AMERICA 13.2.2.1 US TO DOMINATE NORTH AMERICAN GLP-1 AGONISTS MARKET DURING FORECAST PERIOD 13.2.3.1 FAVORABLE FUNDING SCENARIO AND PRESENCE OF STRONG RESEARCH INFRASTRUCTURE TO SUPPORT MARKET GROWTH 13.3.1 MACROECONOMIC OUTLOOK FOR EUROPE 13.3.2.1 EXPERTISE IN BIOTECHNOLOGY AND REPUTATION AS LEADING PHARMACEUTICAL MANUFACTURING HUB TO EXPEDITE MARKET GROWTH 13.3.3.1 GROWING R&D INITIATIVES FOR DEVELOPMENT OF GLP-1 AGONISTS DRUGS TO SUPPORT MARKET GROWTH 13.3.4.1 FAVORABLE REGULATORY SCENARIO AND STRONG RESEARCH INFRASTRUCTURE TO PROPEL MARKET GROWTH 13.3.5.1 PRESENCE OF KEY PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES TO BOOST MARKET GROWTH 13.3.6.1 HIGH INCIDENCE OF DIABETES AND OBESITY TO AUGMENT MARKET ADOPTION OF GLP-1 THERAPEUTIC DRUGS 13.3.7.1 STRONG FOCUS ON PHARMACEUTICAL R&D TO SUPPORT MARKET GROWTH 13.4.1 MACROECONOMIC OUTLOOK FOR ASIA PACIFIC 13.4.2.1 INCREASING ENDORSEMENTS OF ANTI-OBESITY DRUGS BY CELEBRITIES TO DRIVE MARKET ADOPTION 13.4.3.1 HIGH DIABETIC POPULATION AND FAVORABLE REGULATORY SCENARIO TO AID MARKET GROWTH 13.4.4.1 GROWING DEMAND FOR COST-EFFECTIVE AND ACCESSIBLE ANTI-OBESITY MEDICATIONS TO AID MARKET GROWTH 13.4.5.1 SIGNIFICANT GOVERNMENT INVESTMENT IN OBESITY PREVENTION TO FUEL MARKET GROWTH 13.4.6.1 INCREASING STRATEGIC COLLABORATIONS IN OBESITY DRUGS TO PROPEL MARKET GROWTH 13.4.7 REST OF ASIA PACIFIC 13.5.1 MACROECONOMIC OUTLOOK FOR LATIN AMERICA 13.5.2.1 INCREASING PARTNERSHIPS WITH GLOBAL PHARMACEUTICAL COMPANIES AND RISING DIABETES CASES TO DRIVE BRAZILIAN MARKET 13.5.3.1 GROWING DIABETES AND OBESITY PREVALENCE TO SUPPORT MARKET GROWTH 13.5.4 REST OF LATIN AMERICA 13.6.1 MACROECONOMIC OUTLOOK FOR MIDDLE EAST 13.6.2.1 KINGDOM OF SAUDI ARABIA 13.6.2.3 REST OF GCC COUNTRIES 13.6.3 REST OF MIDDLE EAST 13.7.1 GROWING HEALTHCARE AND LIFE SCIENCE INDUSTRY TO SUPPORT GROWTH 13.7.2 MACROECONOMIC OUTLOOK FOR AFRICA 14 COMPETITIVE LANDSCAPE Discover emerging leaders and strategic shifts shaping the GLP-1 agonists market dominance

WEGOVY Injection How Supplied WEGOVY injection is a clear, colorless solution available in cartons containing 4 single-dose pens, 4 single-dose syringes with integrated needles, or 1 single-patient-use pen (WEGOVY FlexTouch) as follows: Recommended Storage Single-dose Pen or Single-dose Syringe Storage Store the WEGOVY prefilled single-dose pen or single-dose syringe in the refrigerator from 2C to 8C (36F to 46F)

While these side effects often diminish over time, they can be challenging for some patients to manage initially

The current data suggest a potential ocular benefit of the GLP-1 receptor agonists and form a basis for future randomized studies on their role in the prevention of AMD